Merck和AstraZeneca报告说,他们的乳癌药物Lynparza将死亡风险降低了28%。 Merck and AstraZeneca report their breast cancer drug Lynparza reduces death risk by 28%.

Merck和AstraZeneca为他们的乳腺癌药物Lynparza发布了长期结果。 Merck and AstraZeneca have released long-term results for their breast cancer drug, Lynparza. 该研究表明,接受药物治疗的病人的死亡风险降低了28%。 The study shows a 28% reduction in the risk of death for patients taking the medication.